Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis, today announced the initial availability of the industry’s first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells, launching a new era for the understanding of disease progression. The Single-cell Multi-omics MRD (scMRD) assay for acute myeloid leukemia (AML) improves on both the sensitivity and specificity of commercial MRD tests used today both in research and to predict cancer recurrence in patients, leveraging the Tapestri® Platform’s unique ability to measure DNA and surface protein expression (or immunophenotype) data from the same cells. Through Mission Bio’s new Early Access Program, pharma and academic partners will perform proof-of-principle studies that broaden understanding of the residual cancer cells that escape treatment for AML by spotlighting the ones that other tests miss.
